GALLO, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.746
AS - Asia 8.208
EU - Europa 5.576
AF - Africa 1.950
SA - Sud America 1.690
OC - Oceania 212
Continente sconosciuto - Info sul continente non disponibili 100
AN - Antartide 2
Totale 36.484
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.743
SG - Singapore 3.226
CN - Cina 1.483
IT - Italia 1.461
BR - Brasile 1.059
HK - Hong Kong 945
VN - Vietnam 557
FI - Finlandia 461
DE - Germania 457
SE - Svezia 381
FR - Francia 287
PL - Polonia 259
RU - Federazione Russa 193
NL - Olanda 187
GB - Regno Unito 180
UA - Ucraina 159
IN - India 150
TR - Turchia 139
AR - Argentina 130
AT - Austria 114
MX - Messico 108
IE - Irlanda 101
ES - Italia 89
IQ - Iraq 84
BJ - Benin 83
AO - Angola 77
EC - Ecuador 75
JO - Giordania 71
ZA - Sudafrica 71
CA - Canada 70
ID - Indonesia 70
VE - Venezuela 70
UZ - Uzbekistan 69
TN - Tunisia 68
CI - Costa d'Avorio 67
JP - Giappone 67
IL - Israele 66
MA - Marocco 66
AM - Armenia 63
KR - Corea 63
IR - Iran 61
PY - Paraguay 60
BB - Barbados 59
BO - Bolivia 59
CH - Svizzera 59
HN - Honduras 59
MK - Macedonia 59
PE - Perù 59
AL - Albania 58
NI - Nicaragua 57
BE - Belgio 56
BY - Bielorussia 56
DZ - Algeria 56
PK - Pakistan 56
ET - Etiopia 55
IS - Islanda 55
PS - Palestinian Territory 55
PT - Portogallo 55
KE - Kenya 54
LB - Libano 54
LV - Lettonia 54
BW - Botswana 53
KG - Kirghizistan 53
ME - Montenegro 53
RS - Serbia 53
CY - Cipro 52
GR - Grecia 52
AE - Emirati Arabi Uniti 51
BF - Burkina Faso 51
CV - Capo Verde 51
SK - Slovacchia (Repubblica Slovacca) 51
BG - Bulgaria 50
HR - Croazia 50
MY - Malesia 50
NZ - Nuova Zelanda 50
PA - Panama 50
SI - Slovenia 50
SO - Somalia 50
AZ - Azerbaigian 49
CW - ???statistics.table.value.countryCode.CW??? 49
CD - Congo 48
CM - Camerun 48
GT - Guatemala 48
JM - Giamaica 48
MG - Madagascar 48
ML - Mali 48
RO - Romania 48
SN - Senegal 48
DK - Danimarca 47
HU - Ungheria 47
TJ - Tagikistan 47
BD - Bangladesh 46
CG - Congo 46
CL - Cile 46
MR - Mauritania 46
NC - Nuova Caledonia 46
TZ - Tanzania 46
XK - ???statistics.table.value.countryCode.XK??? 46
CO - Colombia 45
CR - Costa Rica 45
Totale 34.170
Salva come PNG Salva come JPEG
Città #
Fairfield 2.435
Ashburn 1.735
Singapore 1.729
Woodbridge 1.659
Chandler 1.257
Houston 1.170
Ann Arbor 1.113
Hong Kong 902
Wilmington 887
Cambridge 866
Seattle 845
Santa Clara 709
Jacksonville 520
Boardman 396
Princeton 391
Beijing 364
Medford 207
San Diego 204
Bytom 184
Nanjing 183
Helsinki 161
Roxbury 160
Ho Chi Minh City 153
Milan 149
Los Angeles 137
Des Moines 132
Dong Ket 119
Padova 119
Hanoi 110
São Paulo 107
Norwalk 102
Munich 100
Rome 95
Dublin 88
New York 83
Cotonou 78
Buffalo 71
Luanda 71
Amman 70
Shenyang 69
Guangzhou 67
Hefei 67
Hebei 66
Vienna 65
Abidjan 63
Tashkent 63
Chicago 62
Bridgetown 58
Istanbul 58
Nuremberg 57
Managua 56
Nanchang 55
Yerevan 54
London 48
Riga 48
Dakar 47
Noumea 46
Panama City 46
Baku 45
Bishkek 45
Dushanbe 45
Castries 44
Jiaxing 44
Antananarivo 43
Bamako 43
Nairobi 43
Reykjavik 43
Ulan Bator 43
Addis Ababa 42
Andorra la Vella 42
Kinshasa 42
Harare 41
Havana 41
Nassau 41
Nouakchott 41
Tokyo 41
Warsaw 41
Willemstad 41
Conakry 40
Kingstown 40
Maputo 40
Dar es Salaam 39
Praia 39
Libreville 38
Phnom Penh 38
Brooklyn 37
Kampala 37
Ouagadougou 37
Podgorica 37
Redondo Beach 37
Tianjin 37
Vientiane 37
Minsk 36
Gaborone 35
Kigali 35
Lima 35
Niamey 35
Skopje 35
Montevideo 34
Papeete 34
Totale 22.619
Salva come PNG Salva come JPEG
Nome #
La Sintesi Intratecale di IgG nella Sclerosi Multipla: confronto fra Isoelectricfocusing, IgG index (indice di Link) e Intra-BBB IgG Syn Rate (formula di Tourtellotte). 599
Interleuchina 2 (IL-2) e recettore solubile dell’IL-2 (sIL-2R) nella Sclerosi Multipla. 461
Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study 351
Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study 259
BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset 221
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset 217
Cortical relapses in multiple sclerosis 214
Acute disseminated encephalomyelitis in children: focus on relapsing patients. 210
A new integrated dual time-point amyloid PET/MRI data analysis method 205
Enlarged Virchow Robin spaces associate with cognitive decline in multiple sclerosis 204
Disease-modifying drugs reduce cortical lesion accumulation and atrophy progression in relapsing-remitting multiple sclerosis: results from a 48-month extension study 201
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy 201
Cerebellar gray matter lesions are common in pediatric multiple sclerosis at clinical onset. 196
Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination 194
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: A common, transient and clinically silent phenomenon 192
A case of relapsing-remitting tumour-like inflammation of the central nervous system 190
Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies 190
Heterogeneity of cortical lesions in multiple sclerosis: an MRI perfusion study 189
The parallel analysis of phase sensitive inversion recovery (PSIR) and double inversion recovery (DIR) images significantly improves the detection of cortical lesions in multiple sclerosis (MS) since clinical onset 183
BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset 180
Hyperreflective Foci in the Retina of Active Relapse-Onset Multiple Sclerosis 178
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset 177
Investigation of the neural correlates underlying action observation in multiple sclerosis patients 176
No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab 174
Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study. 173
MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis 173
MRI-detectable cortical lesions in the cerebellum and their clinical relevance in multiple sclerosis 172
Early red nucleus atrophy in relapse-onset multiple sclerosis 170
Acute simultaneous development of brain tumour–like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis 169
The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing-remitting multiple sclerosis. 168
Selective Cerebellar Atrophy Associates with Depression and Fatigue in the Early Phases of Relapse-Onset Multiple Sclerosis 168
Sporadic Creutzfeldt-Jakob disease presenting with isolated progressive non-fluent aphasia in a young woman. 167
Gray matter pathology in MS: A 3-year longitudinal study in a pediatric population 166
'Hidden' factors influencing quality of life in patients with multiple sclerosis 166
Neurofunctional modulation of brain regions by the observation of pointing and grasping actions 163
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. 162
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 162
Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis 162
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. 158
Cortical diffusion-tensor imaging abnormalities in multiple sclerosis: a 3-year longitudinal study. 158
D-KEFS ST failure identifies multiple sclerosis patients with worse objective and self-perceived physical and cognitive disability 158
Slowly Progressive Optic Perineuritis as the First Clinical Manifestation of Sarcoidosis 158
Longitudinal analysis of immune cell phenotypes in early stage multiple sclerosis: distinctive patterns characterize MRI-active patients 156
Prognostic indicators in pediatric clinically isolated syndrome 156
Magnetic Resonance Evidence of Cerebellar Cortical Pathology in Multiple Sclerosis. 156
Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis 155
Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands 155
Neurite orientation dispersion and density imaging discloses early changes in the normal-appearing white matter in paediatric multiple sclerosis 155
Immunological findings in the CSF of HIV-1-infected patients. 154
Central nervous system involvement in HIV infection. 154
Automatic segmentation of gray matter multiple Sclerosis lesions on DIR images 153
Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study 153
Specific smell dysfunctions in relapsing-remitting multiple sclerosis 152
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone 152
Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study 151
Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis 150
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis 150
Cerebrospinal fluid lymphocytes from HIV-infected patients synthesize HIV-specific antibody in vitro. 150
Clinical and diagnostic aspects of multiple sclerosis and acute monophasic encephalomyelitis in pediatric patients: a single centre prospective study. 149
The incidence and significance of anti-natalizumab antibodies. Results from the AFFIRM and SENTINEL . 148
Clinical and cognitive correlates of selective regional retinal thinning in dementia with lewy bodies 148
Free Light-chains of Immunoglobulins In the Cerebrospinal-fluid of Human-immunodeficiency-virus Type-1-infected Patients 148
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification 147
Cortical lesions and cognitive impairment in multiple sclerosis. 146
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis 146
Automatic segmentation of gray matter multiple sclerosis lesions on DIR images 145
Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965-2018 144
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy 144
Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers 144
Transferrin Receptors in the Central Nervous System. 141
Quantification of normal-appearing white matter damage in early relapse-onset multiple sclerosis through neurite orientation dispersion and density imaging 140
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 139
Two years follow up of domain specific cognitive training in relapsing remitting multiple sclerosis: A randomized clinical trial 139
Immunological markers in the cerebrospinal fluid of HIV-1-infected children. 138
Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study 138
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. 137
Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. 137
Lipids in multiple sclerosis. 137
Increased incidence of multiple sclerosis in the Veneto region, Italy. 136
Cortical Pathology in RRMS: Taking a Cue from Four Sisters. 136
Action observation in early RRMS patient. A functional MRI study. 136
Crisi epilettiche all’esordio e al follow-up in ADEM ed sclerosi multipla con esordio in età pediatrica: dati a confronto dalla casistica padovana 136
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis 136
A new T2 lesion in a patient with the clinically isolated syndrome does not necessarily imply a conversion to multiple sclerosis 136
NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis 136
Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis 135
Hyper-reflective foci changes in RRMS under natalizumab therapy 135
The predictive value of gray matter atrophy in clinically isolated syndromes 134
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks 134
Low degree of cortical pathology is associated with benign course of multiple sclerosis. 134
Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study 133
Widespread cortical thinning characterizes patients with MS with mild cognitive impairment 133
Search for HTLV-I and LAV/HTLV-III antibodies in serum and CSF of multiple sclerosis patients. 133
Cerebrospinal fluid analysis in HIV-1-infected children: immunological and virological findings before and after AZT therapy. 133
No MRI evidence of cortical lesions in neuromyelitis optica 133
Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients. 133
Imaging distribution and frequency of cortical lesions in patients with multiple sclerosis 132
Cortical lesion load associates with progression of disability in multiple sclerosis. 131
Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis 130
Blood biomarkers for Alzheimer’s disease with the Lumipulse automated platform: Age-effect and clinical value interpretation 130
Totale 16.787
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.273
article - articoli 89.025
book - libri 236
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 12.634
Totale 208.168
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.689 0 0 0 0 0 158 64 208 283 332 275 369
2021/20223.159 159 351 281 175 173 301 119 321 195 97 275 712
2022/20232.638 546 224 65 297 416 369 23 177 349 19 115 38
2023/20241.390 57 204 181 117 90 112 63 99 49 52 176 190
2024/20256.651 49 594 334 326 1.145 159 250 514 574 265 942 1.499
2025/202611.886 871 1.887 3.196 3.463 2.046 423 0 0 0 0 0 0
Totale 36.670